chrisvoncsefalvay/vaers-outcomes huggingface dataset:
sinus drainage has significantly increased; dealing with joint pain; coughing more phlegm; This is follow-up spontaneous report from a contactable consumer (patient himself). A male patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on 19Mar2021 as dose 1, single for COVID-19 immunisation. The patient medical history includes had a severe case of COVID on an unspecified date in July2020 and was hospitalized. The patient concomitant medications were not reported. It was stated that, he had the usual effects the next day that lasted for a day in a half. On 20Mar2021, the patient experienced sinus drainage has significantly increased, coughing more phlegm, and dealing with joint pain it has almost been two weeks since the first dose. He did not had his second dose and figured he would ask the manufacture of the study. The outcome of the events was unknown.  No follow-up attempts are possible, information about lot/batch number cannot been obtained.
This case was considered medically important. Information regarding PREVNAR was received from a physician, who is a neighbor of the 2-month-old patient who experienced possible febrile seizure. At 2 months of age, the patient received the first dose on an date. Relevant medical history was not provided. Product was administered on an unspecified date.  Dose regimen was 1 dose 1 time per day (intramuscular). Concomitant medications included several unspecified vaccines. The patient experienced possible febrile seizure on an unknown date. Several unspecified vaccines were administered on the same day. The outcome is unknown. No additional information is anticipated. See related case: US-WYE-H01608207 (adverse event, expedited).
R09.02 HYPOXIA 7/2/2021 CKD STAGE 3A (GFR 45-59) R09.02 HYPOXIA 7/2/2021 DM 2 W HYPERGLYCEMIA R09.02 HYPOXIA 7/2/2021 WEAKNESS
Covid toes( feet hurting, red/purple coloration)\last two months symptoms have been only getting worse.; Covid toes( feet hurting, red/purple colorationlast two months symptoms have been only getting worse.; Felt awfull; hair loss/last two months symptoms have been only getting worse; intense rash in the scalp/last two months symptoms have been only getting worse; Experienced 101F fever; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Covid toes( feet hurting, red/purple coloration)\last two months symptoms have been only getting worse.), SKIN DISCOLOURATION (Covid toes( feet hurting, red/purple colorationlast two months symptoms have been only getting worse.), FEELING ABNORMAL (Felt awfull), ALOPECIA (hair loss/last two months symptoms have been only getting worse) and RASH (intense rash in the scalp/last two months symptoms have been only getting worse) in a 25-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 037C21A and 003C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included COVID-19. Concurrent medical conditions included Stress. Concomitant products included TRAZODONE for Stress.   On 27-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Not applicable) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Covid toes( feet hurting, red/purple coloration)\last two months symptoms have been only getting worse.), SKIN DISCOLOURATION (Covid toes( feet hurting, red/purple colorationlast two months symptoms have been only getting worse.), FEELING ABNORMAL (Felt awfull), ALOPECIA (hair loss/last two months symptoms have been only getting worse), RASH (intense rash in the scalp/last two months symptoms have been only getting worse) and PYREXIA (Experienced 101F fever). The patient was treated with CLOBETASOL for Dermatitis and Psoriasis, at an unspecified dose and frequency; SODIUM PROPIONATE (PROPIONATE) for Dermatitis and Psoriasis, at an unspecified dose and frequency and CICLOPIROX for Dermatitis and Psoriasis, at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (Covid toes( feet hurting, red/purple coloration)\last two months symptoms have been only getting worse.), SKIN DISCOLOURATION (Covid toes( feet hurting, red/purple colorationlast two months symptoms have been only getting worse.), FEELING ABNORMAL (Felt awfull), ALOPECIA (hair loss/last two months symptoms have been only getting worse), RASH (intense rash in the scalp/last two months symptoms have been only getting worse) and PYREXIA (Experienced 101F fever) outcome was unknown.            This case was linked to MOD-2021-339439 (Patient Link).
injection site redness; Injection site swelling; shoulder pain; knots in shoulder muscle; decreased arm mobility; difficulty with daily activities; This case was reported by a physician via call center representative and described the occurrence of injection site erythema in a 58-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Influenza vaccine (received vaccine dose years ago from  reporting date). Concomitant products included LEVOTHYROXINE.   On 11th October 2019, the patient received the 1st dose of Shingrix (intramuscular). On an unknown date, less than 2 months after receiving Shingrix, the patient experienced injection site erythema, injection site swelling, shoulder pain, local swelling, mobility decreased and activities of daily living impaired. On an unknown date, the outcome of the injection site erythema and injection site swelling were recovered/resolved and the outcome of the shoulder pain and local swelling were not recovered/not resolved and the outcome of the mobility decreased and activities of daily living impaired were unknown.   It was unknown if the reporter considered the injection site erythema, injection site swelling, shoulder pain, local swelling, mobility decreased and activities of daily living impaired to be related to Shingrix.  Additional details were reported as follows: On 11th October 2019, The patient received first dose of Shingrix and experienced injection site redness and swelling that has resolved. The patient also experienced shoulder pain and knots in her shoulder muscle that persisted and resulted in decreased arm mobility and difficulty with daily activities. This case has been linked with US2019AMR225727, reported by same reporter.
Right arm hurt after 1st dose; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Right arm hurt after 1st dose) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 010M20A and 025A21A0) for COVID-19 vaccination.     The patient's past medical history included Breast cancer. Previously administered products included for Shingles: Shingrix (The patient completed the vaccination series 3 years ago). Concurrent medical conditions included Heart failure, Lupus syndrome, Shingles and Vision loss (Lost vision in one eye).   On 05-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 06-Feb-2021, the patient experienced PAIN IN EXTREMITY (Right arm hurt after 1st dose). On 07-Feb-2021, PAIN IN EXTREMITY (Right arm hurt after 1st dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient takes unspecified concomitant medications for autoimmune conditions and mild pain. No treatment medication use was provided by the reporter.   This case was linked to MOD-2021-228310 (Patient Link).
Found patient slumped over wheel in car post vaccine. She was alert and oriented and said she felt dizzy. EMS checked her out and she said she felt fine and left the site
DIZZY; FOGGY MINDED; ACHES; NAUSEA; This spontaneous report received from a patient concerned a male of unspecified age. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 01-APR-2021 for prophylactic vaccination. Batch number was not reported. Per procedure, no follow up will be requested for this case. No concomitant medications were reported. On APR-2021, the subject experienced dizzy. On APR-2021, the subject experienced foggy minded. On APR-2021, the subject experienced aches. On APR-2021, the subject experienced nausea. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from aches, and nausea, and had not recovered from dizzy, and foggy minded. This report was non-serious.
Pt reported sudden onset of abdominal pain rated 2/10 and diarrhea at 1445. Pt reported no itchiness and no hives. Vitals assessed. BP 110/60 , HR 74, 99% O2 RA, RR 16. Pt reported last oral intake at 1220. Patient given water and advised to stay for 15 minutes.  At approx. 1500, vitals reassessed  bp 100/50, hr 63, O2 99%. Patient  asked to stay  and vitals reassessed at at 1513.  Patient stated she was feeling much better. 110/60 BP, 65 BPM and 99% O2 room air. Patient left facility with steady gait and unlabored breathing at approx. 1517 with husband.
Sudden onset of urticaria with wheals and hives located on face, trunk and buttocks.
CHRONIC HYPERCAPNIC RESPIRATORY FAILURE ACUTE ON CHRONIC RESPIRATORY FAILURE RESPIRATORY FAILURE, UNSPECIFIED ACUITY HYPOXEMIC RESPIRATORY FAILURE, UNSPECIFIED ACUITY
soreness at first.  One hour after dizzy, lightheaded.  few hours later stuffy chest tight, wheezing, fever,, fatigue, chills.  2 weeks later  red welt 3 1/2 in by 6 in on site of vaccine and itchy. lasted 1 1/2 weeks.  Low grade fever for 3 weeks  fatigue continues
Received 1st dose 29Apr2021 has not received 2nd dose; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Received 1st dose 29Apr2021 has not received 2nd dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 29-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Apr-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Received 1st dose 29Apr2021 has not received 2nd dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Received 1st dose 29Apr2021 has not received 2nd dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The pharmacist isnot aware of any side effects due to the missed second vaccine dose.  No concomitant medications information was provided No treatment information were provided
Diffuse hives, difficulty breathing and swallowing. BP 137/90 HR 90 T 97 O2 100% sat. BENADRYL 25mg IV x2. SOLU MEDROL 125mg IV. PEPCID 40mg. EPIPEN 0.3mg 3x. WBC, 6.5; Hct, 40; Plat, 190; Na, 141; K+, 3.5; Gluc, 97. Admitted. States has hx of unknown "allergy" has seen allergist tests negative.
Various side effects; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Various side effects) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Various side effects). At the time of the report, VACCINATION COMPLICATION (Various side effects) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment information provided. No concomitant medication provided.
patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were reported.  The reporter stated that, their facility had not been able to download the digital data logger, they had been put on hold by the state at the moment. There had been no power outages that would have impacted the Moderna vaccine.   It was reported that, the facility was unable to download the digital data logger, they would need to treat this issue as a temperature excursion. The data logger was unable to download for the months of Dec-2021, Jan-2022, and Feb-2022. The reporter did not have any questions and wanted to report this to Moderna.  The reporter stated that no adverse reactions were reported by any patients.
A physician reported that a male pt received Pnu-Imune 23 and 1999-2000 formula influenza virus vaccines on 10/19/99. On 10/20/99, he developed cellulitis and was seen in the physician's office. He was prescribed an unspecified antibiotic. This is 1 of 2 pts from this facility who experienced this event following receipt of Pnu-Imune 23 (lot 459040); the other was serious. See related MCN HQ3303122OCT1999. Additional information received from the physician on 12/7/99, indicated that the pt recovered.
I haven't had my periods in a while but after the vaccination I have been having my periods which is weird. I was not expecting to have the periods again.
330PM p/recvd vax pt felt dizzy sat back down in chair p/which lost consciousness about 10-15 seconds observed jerking movements of the extremities; color was also pale; lips were pale; also lost bladder control @ this time;
Post vaccine syncopal event w/ onset approximately 1min post vaccine administration, lasting <10 seconds.  Accompanied by nausea.  Pt with known hx of similar post vaccine / needle events.
pt temp spiked to 103 by 6PM & pt cried cont for >3hr;mom treated w/APAP & bathed w/cool washcloths;pt would sleep @ intervals but did cont to run a fever & cry for the next 24hr;next morning mom contacted MD & was instructed to monitor pt
right ear is ringing; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 34 year-old male patient received bnt162b2 (BNT162B2), administered in arm right, administration date 17Apr2021 12:30 (Lot number: EW0170) at the age of 34 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: TINNITUS (non-serious) with onset 23Apr2021, outcome "unknown", described as "right ear is ringing". Therapeutic measures were not taken as a result of tinnitus.  Additional information: The patient did not receive any other vaccines within 4 week prior vaccination. The patient had not been diagnosed with COVID-19 prior vaccination and had not been tested for COVID-19 since vaccination. The event happened couple of times and ringing last about a minute.  No follow-up attempts are possible. No further information is expected.
Pt received Pfizer x2.  Pt tested COVID + on 10/6/21 and admitted to hospital for COVID on 10/20/2021. Pt currently on room air and being treating for superimposed bacterial PNA.  Pt received 1 dose of dexamethasone in the ED.
Arm soreness at injection site for 3 weeks, Headaches, extreme muscle aches, fatigue, brain fog, depression that is on going   Generally unwell for 4 weeks following shot. Other symptoms reported to my physician. Now 5 months later concerned that the mood issues are still related for no other reason for it.
itching real bad at the injection site - left arm; redness at the injection site - left arm; swelling at the injection site - left arm; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (itching real bad at the injection site - left arm), VACCINATION SITE ERYTHEMA (redness at the injection site - left arm) and VACCINATION SITE SWELLING (swelling at the injection site - left arm) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history).    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Jan-2021, the patient experienced VACCINATION SITE PRURITUS (itching real bad at the injection site - left arm), VACCINATION SITE ERYTHEMA (redness at the injection site - left arm) and VACCINATION SITE SWELLING (swelling at the injection site - left arm). At the time of the report, VACCINATION SITE PRURITUS (itching real bad at the injection site - left arm), VACCINATION SITE ERYTHEMA (redness at the injection site - left arm) and VACCINATION SITE SWELLING (swelling at the injection site - left arm) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       This case was linked to US-MODERNATX, INC.-MOD-2021-025255 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-025255:Case for patient's husband
Lower back and hip pain Shingles outbreak in L inguinal crease, L lateral knee
Reporting administration error as per Facility.  We contacted Pfizer for expiration dates, Pfizer vaccine specialist advised that the expiration dates were deemed viable at the time of vaccine administration. Pfizer vaccine vials only include manufacturer dates on the box and vials. Therefore, we contacted Pfizer to obtained expiration dates directly from them.  No adverse reactions were reported from the patient at the time of vaccination. No adverse reactions were reported since the administration of vaccination.
Injection 3/11/03. Area red, swollen; started about 3/15-3/16. 3/17 area about 3 inches across redness, warm to touch. Treatment with Ibuprofen, Keflex.
This case was reported by a consumer via call center representative and described the occurrence of extensive swelling of vaccinated limb in a elderly female patient who received Shingrix for prophylaxis. Previously administered products included Shingrix with an associated reaction of injection site erythema (1st dose, refer case US2018192695). On 5th October 2018, the patient received the 2nd dose of Shingrix. On 5th October 2018, less than a day after receiving Shingrix, the patient experienced extensive swelling of vaccinated limb, injection site erythema and injection site warmth. On 11th October 2018, the patient experienced erythematous rash and itchy rash. Rechallenge with Shingrix was positive. On an unknown date, the outcome of the extensive swelling of vaccinated limb, injection site erythema, erythematous rash, itchy rash and injection site warmth were not recovered/not resolved. It was unknown if the reporter considered the extensive swelling of vaccinated limb, injection site erythema, erythematous rash, itchy rash and injection site warmth to be related to Shingrix. Additional details were provided as follows: The age at vaccination was not reported however; the patient was over the age of 65 years. The patient wanted to remain anonymous. The patient's injection site became red, swollen, and hot to the touch on the same day of vaccination. The area was described as 8 inch by 3 inch. On 11th October 2018, 6 days after receiving Shingrix, the patient developed 2 small red bumps on her upper thigh. The night before the reporting date, 2 more bumps appeared on her right wrist and on the day of reporting morning 2 more under her left knee. The bumps were itchy.
I tested positive for COVID-19 on 12/29/2022. I just had fever, but it wasn't particular highly. My temperature was 99.2 which is higher for me. Pulse was 65 and respirations were 16. My chest was hurting but I had 95% oxygen. I had congestion, drainage, and a sore throat. My heart was okay, but I was wheezing. I could feel asthma symptoms and I could feel like my airways were getting constricted. I can go from normal to bad asthma. I was prescribed PAXLOVID 300mg twice daily at urgent care. I also had prednisone 20mg twice daily for 7 days. I had a lot of inflammation around ears, eyes and throat from COVID-19. I felt so awful and I knew something was wrong. I woke up and said my throat hurt and felt deathly. My husband and our son also had COVID-19. We were all vaccinated as well. It wasn't so serious, but it was very spreadable. It took about another week or so to fully recover.
The day after vaccination I had chills, body aches and fatigue The next day I started running a fever as well. The symptoms lasted a week. I was tested for Covid-19 but the test was negative. The fever came and went.  I had a two day period with no fever. The fever returned and I started to have signs of Jaundice. My Bilirubin was up to 14. I was hospitalized for five days as a result of the bilirubin level.  The physician thought that the vaccine caused an inflammatory response because of medical history.  Discharge from hospital was two weeks after vaccine and drain in place for three weeks after.